China NMPA Product Recall - Hybrid Closed Loop Insulin Delivery System

On September 5, 2024, the National Medical Products Administration (NMPA) disseminated information regarding a voluntary Class II recall initiated by Medtronic MiniMed, as reported by its local entity, Medtronic (Shanghai) Management Co., Ltd. This recall targets the company's Hybrid Closed Loop Insulin Delivery System, identifiable by National Medical Device Registration Certificate No. 20233140061. The critical issue prompting this action is the potential for internal capacitor damage within these devices, a risk associated with accidental drops or impacts during use. Such damage could compromise the system's functionality, thereby posing a potential risk to patients relying on its precise insulin delivery.

Operating under the stringent regulatory framework of the NMPA, Medtronic MiniMed is conducting this recall voluntarily to uphold product safety standards. A significant detail is that the specific batches of products involved in this recall were not distributed or imported into the Chinese market. The immediate required action by Medtronic involves managing this global voluntary recall, with comprehensive details on affected product models and specifications available in the 'Medical Device Recall Event Report Form' for stakeholders. This proactive measure underscores the manufacturer's commitment to patient safety and regulatory compliance worldwide, even concerning non-locally distributed products.